| Outcome | Total Comparisons/Studies | All Studies | Oxybutynin ER | Solifenacin | Total Studies | Oxybutynin ER | All Studies | Fesoterodine |
|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | RR (95% CI)[44] | RR (95% CI)[48] | RR (95% CI)[41] | RR (95% CI) | OR (95% CI)[50 | |||
|
| ||||||||
| Versus Oxybutynin IR | Versus Tolterodine IR | Versus Tolterodine ER | ||||||
| Abdominal Pain | 1 | 0.37 (0.02–8.69) | -- | 0.37 (0.02–8.69) | 0 | -- | 0 | -- |
| AEs | 2 | 0.78 (0.61–0.98) | 0.94 (0.59–1.49) | 0.73 (0.56–0.94) | 0 | -- | 1 | 1.37 (1.21–1.55) |
| AEs, Mild | 1 | 1.78 (0.66–4.78) | -- | 1.78 (0.66–4.78) | 0 | -- | 0 | -- |
| AEs, Moderate | 1 | 0.63 (0.33–1.17) | -- | 0.63 (0.33–1.17) | 0 | -- | 0 | -- |
| AEs, Severe | 1 | 0.28 (0.06–1.20) | -- | 0.28 (0.06–1.20) | 0 | -- | 0 | -- |
| Back Pain | 1† (0) | -- | -- | † | 0 | -- | 0 | -- |
| Balance Disorder | 0 | -- | -- | -- | 1† (0) | † | 0 | -- |
| Blurred Vision | 0 | -- | -- | -- | 1 | 5.87 (0.29–119.44) | 0 | -- |
| Confusional State | 1 | 0.37 (0.02–8.69) | -- | 0.37 (0.02–8.69) | 1† (0) | † | 0 | -- |
| Constipation | 1 | 1.85 (0.49–7.03) | -- | 1.85 (0.49–7.03) | 1 | 2.06 (0.64–6.64) | 1 | 1.24 (0.79–1.94) |
| Cough | 1 | 0.56 (0.05–5.79) | -- | 0.56 (0.05–5.79) | 0 | -- | 0 | -- |
| Diarrhea | 0 | -- | -- | -- | 0 | -- | 1 | 0.98 (0.44–2.21) |
| Dizziness | 1 | 9.96 (0.56–176.92) | -- | 9.96 (0.56–176.92) | 1 | 1.18 (0.72–1.93) | 0 | -- |
| Dry Eyes | 1 | 0.22 (0.01–4.42) | -- | 0.22 (0.01–4.42) | 0 | -- | 0 | -- |
| Dry Mouth | 2 | 0.56 (0.38–0.83) | 0.69(0.40–1.18) | 0.46 (0.27–0.78) | 1 | 1.18 (0.72–1.93) | 1 | 2.13 (1.69–2.69) |
| Dry Mouth, Mild | 1 | 1.27 (0.53–3.03) | -- | 1.27 (0.53–3.03) | 0 | -- | 0 | -- |
| Dry Mouth, Moderate | 1 | 0.05 (0.00–0.86) | -- | 0.05 (0.00–0.86) | 0 | -- | 0 | -- |
| Dry Mouth, Severe | 1 | 0.32 (0.07–1.40) | -- | 0.32 (0.07–1.40) | 0 | -- | 0 | -- |
| Dry Skin | 1† (0) | -- | -- | † | 0 | -- | 0 | -- |
| Dry Throat | 1† (0) | -- | -- | † | 0 | -- | 0 | -- |
| Dysgeusia | 1 | 3.32 (0.14–78.25) | -- | 3.32 (0.14–78.25) | 0 | -- | 0 | -- |
| Dyspepsia | 1 | 7.75(0.42–143.52) | -- | 7.75 (0.42–143.52) | 1 | 2.94 (0.60–14.52) | 0 | -- |
| Dysphagia | 1 | 0.16 (0.01–2.93) | -- | 0.16 (0.01–2.93) | 0 | -- | 0 | -- |
| Dysphonia | 1 | 3.32 (0.14–78.25) | -- | 3.32 (0.14–78.25) | 0 | -- | 0 | -- |
| Epistaxis | 1† (0) | -- | -- | † | 0 | -- | 0 | -- |
| Fatigue | 1 | 2.22 (0.44–11.18) | -- | 2.22 (0.44–11.18) | 0 | -- | 0 | -- |
| Gastrointestinal | 1 | 2.37 (0.51–10.91) | 2.37 (0.51–10.91) | -- | 0 | -- | 0 | -- |
| Headache | 1 | 0.37 (0.02–8.69) | -- | 0.37 (0.02–8.69) | 1 | 0.39 (0.08–1.86) | 1 | 1.82 (0.84–3.95) |
| Influenza | 0 | -- | -- | -- | 1 | -- | 0.54 (0.18–1.56) | |
| Insomnia | 0 | -- | -- | -- | 1 (0)† | † | 0 | -- |
| Nasopharyngitis | 1 | 0.22 (0.01–4.42) | -- | 0.22 (0.01–4.42) | 0 | -- | 0 | -- |
| Nausea | 1† (0) | -- | -- | † | 1 | 2.35 (0.22–25.20) | 0 | -- |
| Nervousness | 0 | -- | -- | -- | 1 | 0.39 (0.02–9.39) | 0 | -- |
| Serious AEs | 0 | -- | -- | -- | 0 | -- | 1 | 2.76 (1.16–6.56)C |
| Somnolence | 1 | 1.11 (0.07–16.91) | -- | 1.11 (0.07–16.91) | 1 | 2.35 (0.22–25.20) | 0 | -- |
| Treatment-related AEs | 1 | 0.68 (0.49–0.96) | -- | 0.68 (0.49–0.96) | 0 | -- | 0 | -- |
| Urinary Retention | 0 | -- | -- | -- | 1 | 4.71 (0.54–40.79) | 1 | 7.51 (0.39–145.09) |
| Urinary Tract Infection | 1 | 2.22 (0.21–23.15) | -- | 2.22 (0.21–23.15) | 0 | -- | 0 | -- |
| Vomiting | 0 | -- | -- | -- | 1 | 3.52 (0.15–84.55) | 0 | -- |
*
= I2 >25%;
†
=Adverse Event noted in Study but 0 count
AEs = Adverse Events; CI = confidence intervals; ER = extended release; IR = immediate release; RR= rate ratio